COMPARISON / FOUR EVIDENCE CHAINS
Same Category, Different Burdens of Proof
Mechanism, evidence maturity, and material controls change from one peptide to the next.
The short version
These four compounds share a market label, but little else. GHK-Cu is a copper complex with small topical human studies. BPC-157 is supported mainly by cell and animal research. Tirzepatide is an approved medicine with large controlled trials. Ipamorelin has measurable human pharmacology, one unsuccessful efficacy trial, and no approval [1][8][13][20][21].
That range changes how evidence should be read. A study can support a mechanism or outcome only for the material, model, route, and population it actually tested. It cannot authenticate a new shipment. Import and custody records answer who declared, moved, received, and controlled a sample. Independent analysis answers a narrower chemical or microbiological question about that sample. Neither answers whether an effect will occur outside the studied conditions.
The comparison below keeps those layers side by side. The practical standard stays constant: preserve the documentary trail, test the attributes that matter, and resist transferring credibility from a well-known compound name to an unverified lot.
The comparison grid
| Compound | Main research frame | Human evidence maturity | Regulatory setting | Identity-sensitive point |
|---|---|---|---|---|
| GHK-Cu | Copper handling, matrix signaling, topical delivery | Small topical studies and reviews; broad preclinical mechanisms [1][3][4][5][6] | Cosmetic ingredient context; no approved systemic drug | Free GHK and copper-bound GHK-Cu are different forms |
| BPC-157 | VEGFR2-linked angiogenesis and tissue protection | Tiny pilot record; evidence is overwhelmingly preclinical [8][9][11][12] | Unapproved research compound | Published animal work cannot verify non-regulated material |
| Tirzepatide | Dual GIP and GLP-1 receptor agonism | Large phase-three trials and head-to-head studies [13][16][17] | Approved prescription medicine | Approved-product evidence does not transfer to unrelated preparations |
| Ipamorelin | Ghrelin-receptor activation and growth-hormone release | Small pharmacology studies; clinical endpoint missed [20][21] | Unapproved; prohibited in sport | Acetate form, purity, potency, and sterility require separate controls |
Mechanism is the first difference
GHK-Cu is not a receptor agonist in the same narrow sense as the other systemic compounds here. It carries copper and influences matrix production and multiple signaling programs [2][6][7]. BPC-157 is linked most clearly to blood-vessel growth through VEGFR2, Akt, and nitric-oxide signaling in experimental models [11]. Tirzepatide activates two incretin receptors and produces glucose and appetite effects confirmed in clinical trials [14][17]. Ipamorelin activates the ghrelin receptor and triggers a growth-hormone pulse [21].
These differences dictate analytical priorities. Coordination state is unusually important for GHK-Cu. Sequence and related impurities are central for any peptide. Biological potency may matter for receptor agonists. Sterility and endotoxin are separate attributes whenever an experiment requires sterile material. No generic “purity” number covers every question.
Evidence maturity is the second difference
Tirzepatide has the strongest human outcomes evidence in the set: large randomized trials measured weight and glycated-hemoglobin changes, and pooled work examined specific safety signals [13][15][16][17]. GHK-Cu has human topical and ex vivo work, but sample sizes are modest and broader claims lean on mechanistic literature [1][2][3][5].
BPC-157 has striking preclinical breadth and very little human confirmation. Its first-in-human pilot included only two adults, while a recent review emphasized the absence of rigorous large trials [8][9]. Ipamorelin sits differently: human studies show pharmacology, yet the postoperative efficacy trial missed its primary endpoint [20][21]. Calling all four “research peptides” can conceal this gradient. Evidence maturity should be stated before an effect is summarized.
What the paperwork can establish
A well-kept import file can establish declared origin, dates, parties, quantities, lot identifiers, and the route a shipment followed. A custody file can document seal condition, storage, transfers, sample splitting, and delivery to an analytical laboratory. These records are valuable because they make discrepancies traceable.
They still depend on accurate declarations and controlled linkage. A certificate without a verifiable lot relationship may describe another sample. A laboratory report without custody detail may be analytically sound yet disconnected from the vial at hand. Even a correctly linked result has a defined scope: identity testing is not sterility testing; sterility is not concentration; concentration is not biological activity.
This limitation is most visible when a famous evidence base is nearby. Tirzepatide trials validate specific regulated products [13][16][17]. They do not validate material with a matching customs description. The same logic applies to every compound, even when the published record is preclinical.
A disciplined reading order
Begin with the claim being made. Next identify the exact molecule and form, then the tested material, model, route, comparator, and outcome. After that, assess study design and replication. Only then consider whether the result bears on a new sample or proposed experiment.
For supply records, begin with the declared identity and lot. Trace every handoff. Confirm that the analytical sample came from the received lot under documented conditions. Read the laboratory method and its limits. Keep each result attached to the attribute it measures.
This sequence does not make uncertainty disappear. It makes uncertainty visible and prevents a document from doing argumentative work it cannot support. The individual pages provide the compound-level evidence; the shared reference register preserves the source path.